Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:37:19.661Z.
Calculation as of: 2026-10-06T16:37:19.661Z.
Quote observation: 2026-10-06T16:35:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bcc3f1894ec499320e43c54a24f2662d6ad9e54feca4b92c79248349e67b8166
PE RATIO
N/A
Market Cap
$4.53M
PE Ratio
N/A
TTM Avg
79.42
3Y Avg
79.42
5Y Avg
79.42
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRI Bio, Inc. (GRI) | $4.16M | N/A | N/A | N/A | N/A |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.11M | N/A | N/A | N/A | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.21M | N/A | N/A | N/A | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.01M | N/A | 1.58 | 1.58 | 1.58 |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.38M | N/A | 1.25 | 1.25 | 1.25 |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.82M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.53M | N/A | 79.42 | 79.42 | 79.42 |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.61M | N/A | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.64M | N/A | N/A | N/A | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.77M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.91
Forward EPS (Est.)
$-3.89
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
